Biological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma

设为首页

收藏本站

网站地图 | English | 公务邮箱

About the library

Background
History
Leadership
Organization

Readers' Guide

Opening Hours
Collections
Help Via Email

Publications

Electronic Information Resources

Biological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma

详细信息查看全文

作者：M. Jebali ; R. Elaidi ; M. Brizard ; J. Fouque ; C. Takouchop ; B. Sabatier…
关键词：Drug ; related side effects ; Adverse reactions ; mTOR inhibitors ; Metastatic renal cell carcinoma ; Biomarkers
刊名：BMC Cancer
出版年：2017
出版时间：December 2017
年：2017
卷：17
期：1
全文大小：411KB
刊物主题：Cancer Research; Oncology; Surgical Oncology; Health Promotion and Disease Prevention; Biomedicine, general; Medicine/Public Health, general;
出版者：BioMed Central
ISSN：1471-2407
卷排序：17

文摘

BackgroundMetabolic toxicities of mTOR inhibitors (mTORi) are well characterized. The purpose of the study was to investigate the relationship between these metabolic toxicities and mTORi efficacy.